Governance Guidance for Biopharma Board Members
Experience-based counsel for the people who sit in the boardroom and make the decisions. Not theory. Not checklists. The real work of governing clinical-stage companies.
Read the LatestWhat We Cover
Governance Fundamentals
The foundational knowledge that generic governance resources don't teach
Browse →Clinical-Stage Decision Making
The board's role in the decisions that define clinical-stage companies
Browse →Capital & Strategic Transactions
Financial governance, fundraising oversight, and exit preparation
Browse →Board Dynamics & Effectiveness
The human and organizational dimensions of board governance
Browse →Recent Articles
Related-Party Transactions: Governing the Normal Condition
In a clinical-stage company, related-party transactions are not an aberration to be stamped out. They are the ordinary texture of how these companies get built. The governance question is not how to avoid them but how to handle them routinely, before any one of them becomes a problem.
Strategic Partnerships vs. Acquisition: Governance Considerations
When a company can either partner an asset or sell itself, the board is not choosing between two prices. It is choosing between two different futures, with different risks, different conflicts around the table, and a decision that is far less symmetrical than it appears.
Down Rounds and Board Governance
A down round looks like a valuation problem. It is actually a conflict problem — one in which the people deciding the terms are frequently the same people supplying the money, and the protection the board needs has to be built before the terms are set.
Stay Informed
A weekly newsletter with governance insights, case studies, and analysis for biopharma board members.
No spam. Unsubscribe anytime.